BR0306919A - Métodos para reduzir ou suprimir a efetividade adversa da terapia de l-dopa e/ou do agonista da dopamina, e para tratamento moderado de l-dopa, composição para tratamento moderado de l-dopa, método para tratar doença de parkinson e/ou complicações motoras de l-dopa, composição para o tratamento da doença de parkinson, e, métodos para prolongar o tratamento eficaz da doença de parkinson, e para tratar os distúrbios de movimento - Google Patents
Métodos para reduzir ou suprimir a efetividade adversa da terapia de l-dopa e/ou do agonista da dopamina, e para tratamento moderado de l-dopa, composição para tratamento moderado de l-dopa, método para tratar doença de parkinson e/ou complicações motoras de l-dopa, composição para o tratamento da doença de parkinson, e, métodos para prolongar o tratamento eficaz da doença de parkinson, e para tratar os distúrbios de movimentoInfo
- Publication number
- BR0306919A BR0306919A BR0306919-2A BR0306919A BR0306919A BR 0306919 A BR0306919 A BR 0306919A BR 0306919 A BR0306919 A BR 0306919A BR 0306919 A BR0306919 A BR 0306919A
- Authority
- BR
- Brazil
- Prior art keywords
- dopa
- treatment
- disease
- parkinson
- methods
- Prior art date
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title abstract 15
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract 15
- 238000000034 method Methods 0.000 title abstract 11
- 208000018737 Parkinson disease Diseases 0.000 title abstract 9
- 239000000203 mixture Substances 0.000 title abstract 5
- 239000003136 dopamine receptor stimulating agent Substances 0.000 title abstract 4
- 208000016285 Movement disease Diseases 0.000 title abstract 3
- 230000002411 adverse Effects 0.000 title abstract 3
- 238000011292 agonist therapy Methods 0.000 title 1
- 229940121359 adenosine receptor antagonist Drugs 0.000 abstract 4
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 abstract 4
- 101150051188 Adora2a gene Proteins 0.000 abstract 3
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"MéTODOS PARA REDUZIR OU SUPRIMIR A EFETIVIDADE ADVERSA DA TERAPIA DE L-DOPA E/OU DO AGONISTA DA DOPAMINA, E PARA TRATAMENTO MODERADO DE L-DOPA, COMPOSIçãO PARA TRATAMENTO MODERADO DE L-DOPA, MéTODO PARA TRATAR DOENçA DE PARKINSON E/OU COMPLICAçõES MOTORAS DE L-DOPA, COMPOSIçãO PARA O TRATAMENTO DA DOENçA DE PARKINSON, E, MéTODOS PARA PROLONGAR O TRATAMENTO EFICAZ DA DOENçA DE PARKINSON, E PARA TRATAR OS DISTúRBIOS DE MOVIMENTO". A presente invenção diz respeito a métodos de tratamento de distúrbios do movimento, mediante administração de uma quantidade eficaz de um ou mais antagonistas do receptor da adenosina A~ 2A~, a um paciente em necessidade deste tratamento. A presente invenção também fornece métodos para reduzir os efeitos adversos da L-DOPA em pacientes que estejam recebendo a terapia da L-DOPA no tratamento da doença de Parkinson. A presente invenção ainda fornece métodos e composições para tratar de pacientes com a doença de Parkinson com doses subclinicamente eficazes da L-DOPA mediante combinação do tratamento da L-DOPA com uma quantidade eficaz de um ou mais antagonistas do receptor da adenosina A2A (isto é, um efeito moderado da L-DOPA). A presente invenção ainda fornece métodos de tratamento eficaz da doença de Parkinson mediante a coadministração de pelo menos um antagonista do receptor da adenosina A2A, L-DOPA e um agonista da dopamina e/ou um inibidor de COMT e/ou um inibidor de MAO. A presente invenção ainda fornece métodos de prolongar o tratamento eficaz da doença de Parkinson mediante administração de um antagonista do receptor da adenosina A~ 2A~ isoladamente ou junto com um agonista da dopamina, e/ou um inibidor de COMT, e/ou um inibidor de MAO sem administração prévia ou subseq³ente da L-DOPA, retardando o início da complicação motora da L-DOPA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35241302P | 2002-01-28 | 2002-01-28 | |
| PCT/US2003/002658 WO2003063876A2 (en) | 2002-01-28 | 2003-01-28 | Methods of treating patients suffering from movement disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0306919A true BR0306919A (pt) | 2004-11-09 |
Family
ID=27663091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0306919-2A BR0306919A (pt) | 2002-01-28 | 2003-01-28 | Métodos para reduzir ou suprimir a efetividade adversa da terapia de l-dopa e/ou do agonista da dopamina, e para tratamento moderado de l-dopa, composição para tratamento moderado de l-dopa, método para tratar doença de parkinson e/ou complicações motoras de l-dopa, composição para o tratamento da doença de parkinson, e, métodos para prolongar o tratamento eficaz da doença de parkinson, e para tratar os distúrbios de movimento |
Country Status (16)
| Country | Link |
|---|---|
| US (7) | US20040198753A1 (pt) |
| EP (4) | EP1469855A2 (pt) |
| JP (3) | JP4376630B2 (pt) |
| KR (5) | KR101166000B1 (pt) |
| CN (3) | CN101822676A (pt) |
| AU (2) | AU2003207734C1 (pt) |
| BR (1) | BR0306919A (pt) |
| CA (2) | CA2473864C (pt) |
| CO (1) | CO5601022A2 (pt) |
| EA (1) | EA200400982A1 (pt) |
| ES (2) | ES2686123T3 (pt) |
| HU (2) | HUE043353T2 (pt) |
| MX (1) | MXPA04007299A (pt) |
| PT (2) | PT2942082T (pt) |
| TR (1) | TR201903603T4 (pt) |
| WO (1) | WO2003063876A2 (pt) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2348371B (en) * | 2000-03-14 | 2001-04-04 | Soares Da Silva Patricio | Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease |
| ES2686123T3 (es) * | 2002-01-28 | 2018-10-16 | Kyowa Hakko Kogyo Co., Ltd | Antagonistas del receptor A2A para su uso en el tratamiento de trastornos del movimiento |
| MXPA05001461A (es) † | 2002-08-30 | 2005-06-03 | Kyowa Hakko Kogyo Kk | Antagonistas del receptor a2a de adenosina para el tratamiento del sindrome de las piernas inquietas o trastornos relacionados. |
| US20060128694A1 (en) * | 2002-12-19 | 2006-06-15 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
| US20060106040A1 (en) * | 2002-12-19 | 2006-05-18 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
| MXPA05006790A (es) * | 2002-12-19 | 2005-09-08 | Schering Corp | Usos de antagonistas del receptor adenosina a2a. |
| AR056615A1 (es) * | 2002-12-27 | 2007-10-17 | Kyowa Hakko Kogyo Kk | Un metodo de tratamiento de trastornos de la conducta |
| TW200507850A (en) | 2003-07-25 | 2005-03-01 | Kyowa Hakko Kogyo Kk | Pharmaceutical composition |
| DE10361258A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
| US20050197385A1 (en) * | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
| DE102004014841B4 (de) * | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
| EP1824495A2 (en) * | 2004-12-03 | 2007-08-29 | ProteoSys AG | Finasteride, dutasteride and related compounds for preventing/treating neurologically-associated disorders |
| MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
| ES2385702T3 (es) * | 2005-06-07 | 2012-07-30 | Kyowa Hakko Kirin Co., Ltd. | Antagonistas de A2A para uso en el tratamiento de trastornos de la motricidad |
| US9066903B2 (en) * | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
| US8802002B2 (en) | 2006-12-28 | 2014-08-12 | 3M Innovative Properties Company | Dimensionally stable bonded nonwoven fibrous webs |
| US20090054468A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
| US20090118376A1 (en) * | 2007-11-02 | 2009-05-07 | Ru-Band Lu | Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia |
| DK2306899T3 (da) | 2008-06-12 | 2014-11-10 | Amygdala Pty Ltd | Påvisning af hypokinetiske og/eller hyperkinetiske tilstande |
| CA2750265A1 (en) * | 2009-01-20 | 2010-07-29 | Marc Cantillon | Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease |
| TWI548411B (zh) | 2009-04-28 | 2016-09-11 | Kyowa Hakko Kirin Co Ltd | Exercise disorder treatment |
| WO2012060844A1 (en) * | 2010-11-05 | 2012-05-10 | Biotie Therapies, Inc | A2a antagonists as cognition and motor function enhancers |
| CA2875330A1 (en) * | 2012-06-05 | 2013-12-12 | International Stem Cell Corporation | Method of prevention of neurological diseases |
| US9012640B2 (en) * | 2012-06-22 | 2015-04-21 | Map Pharmaceuticals, Inc. | Cabergoline derivatives |
| US10292635B2 (en) | 2013-03-01 | 2019-05-21 | Global Kinetics Pty Ltd | System and method for assessing impulse control disorder |
| US10040817B2 (en) | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| JP6381883B2 (ja) * | 2013-10-04 | 2018-08-29 | 国立大学法人千葉大学 | 不随意運動の予防及び／又は治療組成物 |
| WO2015131244A1 (en) | 2014-03-03 | 2015-09-11 | Global Kinetics Corporation Pty Ltd | Method and system for assessing motion symptoms |
| WO2016148260A1 (ja) * | 2015-03-17 | 2016-09-22 | 協和発酵キリン株式会社 | 医薬組成物 |
| US10653699B2 (en) | 2015-06-19 | 2020-05-19 | Biotie Therapies, Inc. | Controlled-release tozadenant formulations |
| CN109414417A (zh) * | 2016-03-17 | 2019-03-01 | 约翰·霍普金斯大学 | 通过paris的法尼基化预防或治疗帕金森症的方法 |
| EP3436013A4 (en) | 2016-03-31 | 2019-11-13 | Versi Group, LLC | COMPOSITIONS BASED ON OPIACE RECEPTOR DELTA / OPAACEOUS RECEPTOR DELTA OPTIONAL AGONIST, AND METHODS FOR TREATING PARKINSON'S DISEASE |
| WO2018013951A1 (en) * | 2016-07-15 | 2018-01-18 | Northwestern University | Targeting adenosine a2a receptors for the treatment of levodopa-induced dyskinesias |
| EP3943157A4 (en) | 2019-03-21 | 2022-12-28 | Kyowa Kirin Co., Ltd. | AGENT FOR THE TREATMENT OF PARKINSON'S DISEASE |
| EP3714888A1 (en) * | 2019-03-25 | 2020-09-30 | Assistance Publique - Hôpitaux De Paris | Compounds for use in the treatment of adcy5-related dyskinesia |
| JP7382737B2 (ja) * | 2019-05-13 | 2023-11-17 | 東和薬品株式会社 | イストラデフィリン製剤 |
| WO2022167778A1 (en) | 2021-02-02 | 2022-08-11 | Haiku Therapeutics Ltd | Ebselen as adenosine receptor modulator |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0559893B1 (en) | 1990-10-18 | 1999-02-03 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivative |
| US5484920A (en) * | 1992-04-08 | 1996-01-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for Parkinson's disease |
| CA2116967C (en) | 1992-07-08 | 2003-08-19 | Fumio Suzuki | Antidepressants |
| EP0666079B1 (en) | 1993-07-27 | 2001-11-07 | Kyowa Hakko Kogyo Co., Ltd. | Remedy for parkinson's disease |
| US5703085A (en) | 1994-02-23 | 1997-12-30 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
| AU743910B2 (en) | 1997-03-24 | 2002-02-07 | Kyowa Hakko Kirin Co., Ltd. | {1,2,4}triazolo{1,5-c}pyrimidine derivatives |
| ATE325610T1 (de) * | 1997-09-05 | 2006-06-15 | Kyowa Hakko Kogyo Kk | Xanthinderivative zur behandlung von hirnischämie |
| EP0975345A1 (en) * | 1997-11-26 | 2000-02-02 | Cerebrus Pharmaceuticals Limited | (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders |
| WO1999035147A1 (fr) | 1998-01-05 | 1999-07-15 | Eisai Co., Ltd. | Derives de purine et antagonistes du recepteur a2 d'adenosine utiles comme moyens de prevention/traitement du diabete |
| WO1999043678A1 (fr) | 1998-02-24 | 1999-09-02 | Kyowa Hakko Kogyo Co., Ltd. | Medicaments et prophylaxie contre la maladie de parkinson |
| GB9819382D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds I |
| GB9819384D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
| IL142128A0 (en) | 1998-09-22 | 2002-03-10 | Kyowa Hakko Kogyo Kk | [1,2,4] triazolo [1,5-c] pyrimidine derivatives |
| WO2000069464A1 (fr) | 1999-05-12 | 2000-11-23 | Fujisawa Pharmaceutical Co., Ltd. | Nouvelle utilisation |
| GB9915437D0 (en) * | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
| CN1166666C (zh) | 1999-07-02 | 2004-09-15 | 卫材株式会社 | 缩合咪唑化合物和治疗糖尿病的药物 |
| FR2796759B1 (fr) | 1999-07-23 | 2001-11-02 | Gemplus Card Int | Minicarte a circuit integre et procede pour son obtention |
| US6355653B1 (en) | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
| AUPQ441499A0 (en) | 1999-12-02 | 2000-01-06 | Fujisawa Pharmaceutical Co., Ltd. | Novel compound |
| KR100521735B1 (ko) | 2000-02-25 | 2005-10-17 | 에프. 호프만-라 로슈 아게 | 아데노신 수용체 조절인자 |
| HUP0300927A2 (hu) | 2000-04-26 | 2003-07-28 | Eisai Co., Ltd. | Új pirimidinszármazékok és ezeket tartalmazó defekációt elősegítő gyógyszerkészítmények |
| PT1283839E (pt) | 2000-05-26 | 2005-08-31 | Schering Corp | Antagonistas do receptor a2a da adenosina |
| AU8181701A (en) | 2000-06-21 | 2002-01-02 | Hoffmann La Roche | Benzothiazole derivatives |
| KR100804111B1 (ko) | 2000-08-11 | 2008-02-18 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 2-아미노피리딘 화합물 및 그의 의약 용도 |
| GB0100620D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical cokpounds V |
| JP2004529916A (ja) * | 2001-04-09 | 2004-09-30 | ニューロサーチ、アクティーゼルスカブ | パーキンソン病の治療において神経栄養活性化合物と組み合わせたアデノシンａ２ａレセプターアンタゴニスト |
| ES2686123T3 (es) * | 2002-01-28 | 2018-10-16 | Kyowa Hakko Kogyo Co., Ltd | Antagonistas del receptor A2A para su uso en el tratamiento de trastornos del movimiento |
| MXPA05001461A (es) * | 2002-08-30 | 2005-06-03 | Kyowa Hakko Kogyo Kk | Antagonistas del receptor a2a de adenosina para el tratamiento del sindrome de las piernas inquietas o trastornos relacionados. |
| EP1631294B1 (en) * | 2003-06-10 | 2010-09-15 | Kyowa Hakko Kirin Co., Ltd. | A method of treating an anxiety disorder |
| TW200507850A (en) * | 2003-07-25 | 2005-03-01 | Kyowa Hakko Kogyo Kk | Pharmaceutical composition |
| US9238003B2 (en) * | 2005-02-04 | 2016-01-19 | Auburn University | Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules |
-
2003
- 2003-01-28 ES ES10179406.3T patent/ES2686123T3/es not_active Expired - Lifetime
- 2003-01-28 KR KR1020107029622A patent/KR101166000B1/ko active IP Right Grant
- 2003-01-28 BR BR0306919-2A patent/BR0306919A/pt not_active Application Discontinuation
- 2003-01-28 ES ES15165962T patent/ES2716404T3/es not_active Expired - Lifetime
- 2003-01-28 EP EP03705971A patent/EP1469855A2/en not_active Withdrawn
- 2003-01-28 PT PT15165962T patent/PT2942082T/pt unknown
- 2003-01-28 EP EP10179406.3A patent/EP2260850B1/en not_active Expired - Lifetime
- 2003-01-28 KR KR1020127020629A patent/KR20120103740A/ko not_active Application Discontinuation
- 2003-01-28 EA EA200400982A patent/EA200400982A1/ru unknown
- 2003-01-28 CA CA2473864A patent/CA2473864C/en not_active Expired - Lifetime
- 2003-01-28 KR KR1020047011319A patent/KR101098209B1/ko active IP Right Grant
- 2003-01-28 HU HUE15165962A patent/HUE043353T2/hu unknown
- 2003-01-28 TR TR2019/03603T patent/TR201903603T4/tr unknown
- 2003-01-28 MX MXPA04007299A patent/MXPA04007299A/es active IP Right Grant
- 2003-01-28 PT PT10179406T patent/PT2260850T/pt unknown
- 2003-01-28 EP EP15165962.0A patent/EP2942082B1/en not_active Expired - Lifetime
- 2003-01-28 HU HUE10179406A patent/HUE039348T2/hu unknown
- 2003-01-28 CA CA2813048A patent/CA2813048A1/en not_active Abandoned
- 2003-01-28 CN CN201010145019A patent/CN101822676A/zh active Pending
- 2003-01-28 CN CNA038028476A patent/CN1646132A/zh active Pending
- 2003-01-28 WO PCT/US2003/002658 patent/WO2003063876A2/en active Application Filing
- 2003-01-28 US US10/353,240 patent/US20040198753A1/en not_active Abandoned
- 2003-01-28 KR KR1020157016639A patent/KR20150080013A/ko not_active Application Discontinuation
- 2003-01-28 CN CNA2009100075971A patent/CN101543497A/zh active Pending
- 2003-01-28 JP JP2003563566A patent/JP4376630B2/ja not_active Expired - Lifetime
- 2003-01-28 AU AU2003207734A patent/AU2003207734C1/en not_active Expired
- 2003-01-28 KR KR1020107008755A patent/KR20100056569A/ko not_active Application Discontinuation
- 2003-01-28 EP EP09150929A patent/EP2044940A3/en not_active Withdrawn
-
2004
- 2004-07-27 CO CO04071765A patent/CO5601022A2/es not_active Application Discontinuation
-
2006
- 2006-01-06 US US11/326,516 patent/US7727994B2/en not_active Expired - Lifetime
- 2006-01-06 US US11/326,414 patent/US7727993B2/en not_active Expired - Lifetime
-
2008
- 2008-02-08 AU AU2008200611A patent/AU2008200611B2/en not_active Expired
- 2008-11-04 JP JP2008282859A patent/JP5171556B2/ja not_active Expired - Lifetime
-
2011
- 2011-11-16 US US13/297,341 patent/US20120122897A1/en not_active Abandoned
-
2012
- 2012-04-10 JP JP2012089139A patent/JP5612016B2/ja not_active Expired - Lifetime
-
2014
- 2014-03-27 US US14/227,421 patent/US20140249166A1/en not_active Abandoned
-
2017
- 2017-01-24 US US15/413,898 patent/US20170196872A1/en not_active Abandoned
-
2018
- 2018-03-01 US US15/908,974 patent/US20180221377A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0306919A (pt) | Métodos para reduzir ou suprimir a efetividade adversa da terapia de l-dopa e/ou do agonista da dopamina, e para tratamento moderado de l-dopa, composição para tratamento moderado de l-dopa, método para tratar doença de parkinson e/ou complicações motoras de l-dopa, composição para o tratamento da doença de parkinson, e, métodos para prolongar o tratamento eficaz da doença de parkinson, e para tratar os distúrbios de movimento | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| BR0314308A (pt) | Composto, composição farmacêutica, métodos para bloquear uma combinação de mu, kappa, delta ou receptor (heterodìmero) dos mesmos em mamìferos, para tratar ou prevenir obesidade e doenças relacionadas, para suprimir o apetite em um paciente em necessidade deste, e para realizar a perda de peso em um paciente obeso, e, uso de um composto | |
| BRPI0410927A (pt) | métodos terapêuticos e profiláticos para distúrbios neuromusculares | |
| BR0209147A (pt) | Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais | |
| BR0008847A (pt) | Composições analgésicas que compreendemcompostos antiepilépticos, e métodos de uso dasmesmas | |
| BR9908030A (pt) | Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado | |
| US20060233892A1 (en) | Topiramate compositions for treatment of headache | |
| BRPI0408902A (pt) | composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca | |
| EP1348466A3 (en) | Method for treating pain with adenosine-tetraphosphates | |
| EP2335734A3 (en) | Treatment of pain and other alpha 2 adrenergic-mediated conditions | |
| WO2003068171A3 (en) | Method and composition for treatment of inflammation and aids-associated neurological disorders | |
| BRPI0606393A2 (pt) | prevenção de doenças trombóticas com compostos ativos de vitamina d ou similares do mesmo | |
| MX2009008582A (es) | Metodo para la administracion terapeutica de dihidroergotamina para permitir un rapido alivio de la migraña mientras se minimiza el perfil de efectos secundarios. | |
| BR9914419A (pt) | Terapia para melhoria da percepção | |
| BRPI0507657A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo | |
| BRPI0511800A (pt) | tratamento com irinotecano (cpt-11) e um inibidor de egfr | |
| WO2006002096A3 (en) | Low doses of l-citrulline for treating diseases | |
| BRPI0406674A (pt) | Composição para a ministração intranasal de fentanila ou um seu sal farmaceuticamente aceitável, uso de um aditivo farmaceuticamente aceitável, método para o tratamento ou prevenção de dor aguda ou crÈnica, dispositivo para pulverização, e, processo para preparar uma composição | |
| BR0200246A (pt) | Tratamento de combinação para a depressão | |
| JP2005508896A5 (pt) | ||
| AU9551201A (en) | Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates | |
| BRPI0413410A (pt) | co-administração de um polissacarìdeo com um agente quimioterapêutico para o tratamento de cáncer | |
| BR0214497A (pt) | Composição farmacêutica que compreende um agonista do receptor 5ht1 | |
| BRPI0406634A (pt) | Uso de um anagrelìdeo, anagrelìdeo na forma de base, ou um sal farmaceuticamente aceitável do anagrelìdeo, composição farmacêutica não-oral, e dispositivo médido para administração transdérmica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: KYOWA HAKKO KIRIN CO., LTD. (JP) Free format text: NOME ALTERADO DE: KYOWA HAKKO KOGYO CO., LTDA. |
|
| B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |